牛逼_老虎社区_美港股上老虎

聰明的人做多
2023-12-02

牛逼

PATH, ULTA and CAN are among pre market gainers

Jeffs Brands +64%Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.Altimmune +38%pulls back from twice-daily regime of weight-loss drug candidate.Biora Therapeutics +29%clears Biora to begin Phase 1 testing of ulcerative colitis treatment.

PATH, ULTA and CAN are among pre market gainers

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":247436374540296,"tweetId":"247436374540296","gmtCreate":1701447059883,"gmtModify":1701447303177,"author":{"id":3476472488695615,"authorId":3476472488695615,"authorIdStr":"3476472488695615","name":"聰明的人做多","avatar":"https://static.tigerbbs.com/cb283203da58d2b01218c21d403896c0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>牛逼</p></body></html>","htmlText":"<html><head></head><body><p>牛逼</p></body></html>","text":"牛逼","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/247436374540296","repostId":2388681230,"repostType":2,"repost":{"id":"2388681230","pubTimestamp":1701437499,"share":"https://www.laohu8.com/m/news/2388681230?lang=&edition=full","pubTime":"2023-12-01 21:31","market":"us","language":"en","title":"PATH, ULTA and CAN are among pre market gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2388681230","media":"seekingalpha","summary":"Jeffs Brands  +64%Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.Altimmune  +38%pulls back from twice-daily regime of weight-loss drug candidate.Biora Therapeutics  +29%clears Biora to begin Phase 1 testing of ulcerative colitis treatment.","content":"<html><body><ul>\n<li>Neximmune  (NEXI) <font color=\"green\">+338%</font>.</li>\n<li><a href=\"https://laohu8.com/S/JFBR\">Jeffs Brands</a>  (JFBR) <font color=\"green\">+64% </font>Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.\n</li>\n<li>ShiftPixy  (PIXY) <font color=\"green\">+26%</font>.</li>\n<li>Altimmune (ALT) +38% pulls back from twice-daily regime of weight-loss drug candidate.\n</li>\n<li>Biora Therapeutics  (BIOR) +29% clears Biora to begin Phase 1 testing of ulcerative colitis treatment.\n</li>\n<li>Sigma Additive Solutions  (SASI) <font color=\"green\">+31%</font>.</li>\n<li>Clearmind Medicine  (CMND) <font color=\"green\">+22%</font>.</li>\n<li>Elastic (ESTC) +18% Q2 earnings call reease\n</li>\n<li><a href=\"https://laohu8.com/S/FEBO\">Fenbo Holdings Limited</a> (FEBO) <font color=\"green\">+17%</font>.</li>\n<li><a href=\"https://laohu8.com/S/PATH\">UiPath</a> (PATH) <font color=\"green\">+15%</font>.</li>\n<li>Samsara (IOT) <font color=\"green\">+13%</font>.</li>\n<li>Ulta Beauty  (ULTA) <font color=\"green\">+11%</font>.</li>\n<li>GigaCloud Technology  (GCT) +9% Q3 earnings call release\n</li>\n<li>Canaan  (CAN) <font color=\"green\">+3%</font>.</li>\n<li>Pagerduty  (PD) +6% Q3 earnings call release\n</li>\n<li>Taoping  (TAOP) <font color=\"green\">+6%</font>.</li>\n<li>Hongli Group (HLP) <font color=\"green\">+6%</font>.</li>\n<li>Soho House  (SHCO) <font color=\"green\">+5%</font>.</li>\n</ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PATH, ULTA and CAN are among pre market gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPATH, ULTA and CAN are among pre market gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-01 21:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4042179-path-ulta-and-can-are-among-pre-market-gainers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neximmune  (NEXI) +338%.\nJeffs Brands  (JFBR) +64% Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.\n\nShiftPixy  (PIXY) +26%.\nAltimmune (ALT) +38% pulls back from twice-...</p>\n\n<a href=\"https://seekingalpha.com/news/4042179-path-ulta-and-can-are-among-pre-market-gainers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","relate_stocks":{"BK4551":"寇图资本持仓","BK4134":"信息科技咨询与其它服务","BK4122":"互联网与直销零售","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","GCT":"大健云仓","CAN":"嘉楠科技","PIXY":"Shiftpixy Inc.","BK4561":"索罗斯持仓","LU0823411888.USD":"法巴消费创新基金 Cap","BK4097":"系统软件","BK4505":"高瓴资本持仓","CMND":"Clearmind Medicine, Inc.","SHCO":"SOHO HOUSE & CO INC","PATH":"UiPath","PD":"PagerDuty, Inc.","JFBR":"Jeffs Brands","BK4200":"专卖店","BK4142":"酒店、度假村与豪华游轮","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4170":"电脑硬件、储存设备及电脑周边","BK4565":"NFT概念","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4006":"钢铁","BK4539":"次新股","BK4023":"应用软件","ULTA":"Ulta美容","BIOR":"Biora Therapeutics, Inc.","BK4187":"航天航空与国防","NEXI":"NexImmune, Inc.","ESTC":"Elastic N.V.","TAOP":"淘屏","FEBO":"晖宝","BK4585":"ETF&股票定投概念","HLP":"宏力型钢","BK4139":"生物科技","BK4159":"经销商","BK4526":"热门中概股","BK4007":"制药","BK4130":"人力资源与就业服务","ALT":"Altimmune, Inc.","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4196":"保健护理服务","BK4220":"综合零售","IOT":"Samsara, Inc.","BK4588":"碎股"},"source_url":"https://seekingalpha.com/news/4042179-path-ulta-and-can-are-among-pre-market-gainers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2388681230","content_text":"Neximmune  (NEXI) +338%.\nJeffs Brands  (JFBR) +64% Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.\n\nShiftPixy  (PIXY) +26%.\nAltimmune (ALT) +38% pulls back from twice-daily regime of weight-loss drug candidate.\n\nBiora Therapeutics  (BIOR) +29% clears Biora to begin Phase 1 testing of ulcerative colitis treatment.\n\nSigma Additive Solutions  (SASI) +31%.\nClearmind Medicine  (CMND) +22%.\nElastic (ESTC) +18% Q2 earnings call reease\n\nFenbo Holdings Limited (FEBO) +17%.\nUiPath (PATH) +15%.\nSamsara (IOT) +13%.\nUlta Beauty  (ULTA) +11%.\nGigaCloud Technology  (GCT) +9% Q3 earnings call release\n\nCanaan  (CAN) +3%.\nPagerduty  (PD) +6% Q3 earnings call release\n\nTaoping  (TAOP) +6%.\nHongli Group (HLP) +6%.\nSoho House  (SHCO) +5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":688,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}